scholarly journals Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Kathleen R. Brandt ◽  
Christopher G. Scott ◽  
Diana L. Miglioretti ◽  
Matthew R. Jensen ◽  
Amir P. Mahmoudzadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Normal Breast ◽  
Relative Increase ◽  
Absolute Difference ◽  
Rank Test ◽  
Full Field ◽  
Volumetric Density ◽  
Differential Change ◽  
Good Discriminator ◽  
Signed Rank Test

Abstract Background Given that breast cancer and normal dense fibroglandular tissue have similar radiographic attenuation, we examine whether automated volumetric density measures identify a differential change between breasts in women with cancer and compare to healthy controls. Methods Eligible cases (n = 1160) had unilateral invasive breast cancer and bilateral full-field digital mammograms (FFDMs) at two time points: within 2 months and 1–5 years before diagnosis. Controls (n = 2360) were matched to cases on age and date of FFDMs. Dense volume (DV) and volumetric percent density (VPD) for each breast were assessed using Volpara™. Differences in DV and VPD between mammograms (median 3 years apart) were calculated per breast separately for cases and controls and their difference evaluated by using the Wilcoxon signed-rank test. To simulate clinical practice where cancer laterality is unknown, we examined whether the absolute difference between breasts can discriminate cases from controls using area under the ROC curve (AUC) analysis, adjusting for age, BMI, and time. Results Among cases, the VPD and DV between mammograms of the cancerous breast decreased to a lesser degree (− 0.26% and − 2.10 cm3) than the normal breast (− 0.39% and − 2.74 cm3) for a difference of 0.13% (p value < 0.001) and 0.63 cm3 (p = 0.002), respectively. Among controls, the differences between breasts were nearly identical for VPD (− 0.02 [p = 0.92]) and DV (0.05 [p = 0.77]). The AUC for discriminating cases from controls using absolute difference between breasts was 0.54 (95% CI 0.52, 0.56) for VPD and 0.56 (95% CI, 0.54, 0.58) for DV. Conclusion There is a small relative increase in volumetric density measures over time in the breast with cancer which is not found in the normal breast. However, the magnitude of this difference is small, and this measure alone does not appear to be a good discriminator between women with and without breast cancer.

scholarly journals A Large Randomized Trial: Effects of Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer (BC) Survivors on Salivary Cortisol and IL-6

2018 ◽  
Vol 21 (1) ◽  
pp. 39-49 ◽  
Author(s):  
Cecile A. Lengacher ◽  
Richard R. Reich ◽  
Carly L. Paterson ◽  
Melissa Shelton ◽  
Steve Shivers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Stress Reduction ◽  
Salivary Cortisol ◽  
Rank Test ◽  
Signed Rank ◽  
Wilcoxon Signed Rank Test ◽  
Signed Rank Test ◽  
Mindfulness Based Stress Reduction

Breast cancer survivors (BCS) often experience psychological and physiological symptoms after cancer treatment. Mindfulness-based stress reduction (MBSR), a complementary and alternative therapy, has reduced subjective measures of stress, anxiety, and fatigue among BCS. Little is known, however, about how MBSR affects objective markers of stress, specifically the stress hormone cortisol and the pro-inflammatory cytokine interleukin-6 (IL-6). In the present study, BCS ( N = 322) were randomly assigned to a 6-week MBSR program for BC or usual-care control. Measurements of cortisol, IL-6, symptoms, and quality of life were obtained at orientation and 6 weeks. Cortisol and IL-6 were also measured prior to and after the MBSR(BC) class Weeks 1 and 6. The mean age of participants was 56.6 years and 69.4% were White non-Hispanic. Most had Stage I (33.8%) or II (35.7%) BC, and 35.7% had received chemotherapy and radiation. Cortisol levels were reduced immediately following MBSR(BC) class compared to before the class Weeks 1 and 6 (Wilcoxon-signed rank test; p < .01, d = .52–.56). IL-6 was significantly reduced from pre- to postclass at Week 6 (Wilcoxon-signed rank test; p < .01, d = .21). No differences were observed between the MBSR(BC) and control groups from baseline to Week 6 using linear mixed models. Significant relationships with small effect sizes were observed between IL-6 and both symptoms and quality of life in both groups. Results support the use of MBSR(BC) to reduce salivary cortisol and IL-6 levels in the short term in BCS.

Use of microRNA (miR) expression profiling to identify distinct subclasses of triple-negative breast cancers (TNBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1007-1007 ◽  
Author(s):  
Charles L. Shapiro ◽  
Luciano Cascione ◽  
Pierluigi Gasparini ◽  
Francesca Lovat ◽  
Stefania Carasi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Expression Profiling ◽  
Clustering Algorithm ◽  
Medical Center ◽  
Expression Profiles ◽  
Normal Breast ◽  
Rank Test ◽  
Cancer Data

1007 Background: TNBC is divided into basal and non-basal subclasses. To further subclassify TNBC we performed microRNA (miR) expression profiles and linked them to patient overall survival. Methods: During 1996-2005, 365 consecutive TNBC (phenotypically estrogen, progesterone and HER2 negative by immunohistochemistry [IHC]) were identified from the NCCN Breast Cancer Data Base/Tumor Registry at OSU Medical Center. One hundred fifty-eight (43%) formalin-fixed paraffin embedded (FFPE) breast cancer and 40 normal breast tissue blocks were available and tissue cores were obtained for RNA. RNA was isolated using the Ambion recoverall total nucleic acid isolation kit and the expression of ~700 miRs was assessed for each sample using the nanoString nCounter method. A consensus-clustering algorithm (ConsensusClusterPlus, Bioconductor www.bioconductor.org) was used to identify subclasses of TNBC and Kaplan-Meier overall survival curves were compared using the log-rank test. Censoring occurred at the date of death from causes other than breast cancer or at time of the last known follow-up, whichever occurred first. The median follow-up was 67 mo. (range 4-171 mo.). Results: The median age was 52 yrs. (range 20-84 yrs.); 81% white and 9% African-American; stages I, II, and III were 31%, 54% and 15%, respectively; and most patients received adjuvant anthracycline-based regimens with (25%) or without taxanes (75%). The algorithm identified 5 distinct subclasses; 1 clustering with normal breast miR expression whereas the other 4 each had a unique pattern of deregulated miRs. The median overall survivals were significantly different across the 5 cancer subclasses (log-rank p=0.028) (Table). Conclusions: miR expression profiling identifies and discriminates 5 TNBC subclasses, which do not coincide with those identified as basal and non-basal by IHC. Molecular analyses are ongoing to associate the miR-based subclasses with specific clinical features or the expression of specific pathways. [Table: see text]

scholarly journals Area and Volumetric Density Estimation in Processed Full-Field Digital Mammograms for Risk Assessment of Breast Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e110690 ◽  
Author(s):  
Abbas Cheddad ◽  
Kamila Czene ◽  
Mikael Eriksson ◽  
Jingmei Li ◽  
Douglas Easton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Density Estimation ◽  
Full Field ◽  
Volumetric Density

Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 509-509 ◽  
Author(s):  
J. Jacquemier ◽  
F. Penault-Llorca ◽  
H. Mnif ◽  
E. Charafe-Jauffret ◽  
S. Marque ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tissue Microarrays ◽  
Therapeutic Benefit ◽  
Normal Breast ◽  
Phase Iii ◽  
Rank Test ◽  
Cancer Trial ◽  
Er Positive ◽  
The Impact ◽  
Docetaxel Chemotherapy

509 Background: Immunohistochemical profiling studies with TMA classified breast cancer by luminal, normal breast like, HER-2 overexpressing, and basal-like subtypes. The aim of this study was to evaluate the impact of these subclasses in terms of therapeutic benefit for patients (pts) with node positive operable breast cancer included in the phase III trial PACS01. Methods: Among the 1999 pts randomized, 1100 paraffin blocs were collected for TMA. Pts were treated with either arm A: 6 cycles of FEC100 (546 pts) or arm B: docetaxel 100 mg/m2 replaced FEC100 for the last 3 cycles (554 pts). The median follow up was 5 years. The 33 analysed markers explored different pathways: cellular differentiation (CK5/6,8/18,14, P-Cadherin, E-cadherin, α-catenin, β-catenin, AF6, MUC1, Cav1, moesin, Cd10, CD44), proliferation/apoptosis (AuroraA, Tacc2/3, Ki67, CyclinD1, Bcl2, p21, p27), ER related (ER, PR, Gata3), and oncogene/ antioncogene (P53, HER2, EGFR1, Pten, Cmet, Fhit, FGFR, Angiogenin, topoisomeraseIIα). All antibodies were evaluated in quick score. Results: In terms of metastases free survival (MFS) 16 markers harboured a statistical significant value under 20%. The hierarchical clustering for 80% of complete data, identify a cluster of pts (n=531) characterized by the positive expression of EGFR1, Moesin, Pcadherin, and p53, considered as basal-like subtype (BLST). This cluster presented a pejorative predictive value both in Log-rank test (LR) (p=0.002) and in Cox multivariate analysis (HR=0.65; p=0.009), confirmed in overall survival (OS) (LR p<0.0001; cox HR=0.46, p<0.001). BLST pts had a significantly better MFS (LR p=0.05) in the arm B, confirmed in OS (LR p=0.005), as for a more theoretical basal signature and ER negativity (LR MFS p=0.0033, OS p=0.0052; cox MFS HR=0.71 p=0.04, OS HR=0.51 p=0.003). For a second cluster considered as luminal subtype (ER positive and BLST parameters negatives) no difference was observed whatever the arm. Conclusions: The basal-like profile identified in this study is significantly associated to a worst prognostic, but also to a better response to sequential FEC/docetaxel chemotherapy. [Table: see text]

The Influence of Breast Cancer on the Distribution of Cherry Angiomas on the Anterior Thoracic Wall: A Case Series Study

Dermatology ◽  
2018 ◽  
Vol 235 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Antonio Guastafierro ◽  
Vincenzo Verdura ◽  
Bruno Di Pace ◽  
Mario Faenza ◽  
Corrado Rubino
Keyword(s):  
Breast Cancer ◽  
Statistical Significance ◽  
Case Series ◽  
Thoracic Wall ◽  
Rank Test ◽  
P Value ◽  
Unilateral Breast Cancer ◽  
Case Series Study ◽  
Signed Rank Test ◽  
The Difference

Background/Aims: Cherry angiomas (CAs) are one of the most common vascular manifestations of the skin. By and large, these benign lesions often only represent an aesthetic problem. In the literature, few authors have focused on the pathogenesis of these lesions, and some risk factors have been identified, such as the presence of cutaneous and non-skin neoplasias. In this study, the correlation between the distribution of CAs and breast cancer was investigated. Methods: We carried out a study whereby 50 women with unilateral breast cancer and the presence of CAs on the anterior thoracic wall were evaluated, with a particular focus on the difference in the number of CAs between the two haemithoraces. The data was elaborated using the Wilcoxon signed-rank test in order to evaluate whether there was a statistical significance in the distribution of CAs. Results: In 31 patients we found that the number of CAs was greater on the cancerous breast than on the contralateral one (p value <0.0001). This was confirmed both in the group of patients suffering from ductal breast cancer and in the group with early invasive breast tumours. Conclusion: It is not clear whether CAs develop prior to or following breast cancer, indicating the possibility that this cutaneous manifestation could take on a predictive, prognostic development or represent only an epiphenomenon. Further in-depth studies into the pathogenesis of CAs and the relationship with breast cancer could lead to noteworthy diagnostic-therapeutic advances.

scholarly journals Pilot Clinical Study Investigating the Thermal Physiology of Breast Cancer via High-Resolution Infrared Imaging

2021 ◽  
Vol 8 (7) ◽  
pp. 86
Author(s):  
Adolfo Lozano ◽  
Jody C. Hayes ◽  
Lindsay M. Compton ◽  
Fatemeh Hassanipour
Keyword(s):  
Breast Cancer ◽  
Elevated Temperatures ◽  
Infrared Imaging ◽  
Thermal Characteristics ◽  
Rank Test ◽  
Institutional Review Boards ◽  
Breast Cancers ◽  
Unilateral Breast Cancer ◽  
Institutional Review ◽  
Signed Rank Test

This descriptive study investigates breast thermal characteristics in females histologically diagnosed with unilateral breast cancer and in their contralateral normal breasts. The multi-institutional clinical pilot study was reviewed and approved by the Institutional Review Boards (IRBs) at participating institutions. Eleven female subjects with radiologic breast abnormalities were enrolled in the study between June 2019 and September 2019 after informed consent was obtained. Static infrared images were recorded for each subject. The Wilcoxon signed rank test was used to conduct paired comparisons in temperature data between breasts among the eight histologically diagnosed breast cancer subjects (n = 8). Localized temperatures of cancerous breast lesions were significantly warmer than corresponding regions in contralateral breasts (34.0 ± 0.9 °C vs. 33.2 ± 0.5 °C, p = 0.0142, 95% CI 0.25–1.5 °C). Generalized temperatures over cancerous breasts, in contrast, were not significantly warmer than corresponding regions in contralateral breasts (33.9 ± 0.8 °C vs. 33.4 ± 0.4 °C, p = 0.0625, 95% CI −0.05–1.45 °C). Among the breast cancers enrolled, breast cancers elevated temperatures locally at the site of the lesion (localized hyperthermia), but not over the entire breast (generalized hyperthermia).

scholarly journals Walking Exercise Programme (WEP) Menurunkan Cancer Related Fatigue (CRF) Pada Pasien Kanker Payudara Di RSUD. Ibnu Sina Gresik

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Indah Sri Wahyuni ◽  
I Ketut Sudiana ◽  
Herdina Mariyanti
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Rank Test ◽  
Case Group ◽  
Cancer Related Fatigue ◽  
Signed Rank ◽  
Post Test ◽  
Signed Rank Test ◽  
Walking Exercise

Introduction: Development of cancer and the side effect of chemotherapy could lead to Cancer Related Fatigue (CRF) in breast cancer patient that getting worse due to inactivation. Hence, exercise was needed. This aimed of this was to analyze the effect of Walking Exercise Program (WEP) to Cancer Related Fatigue.Methode: This study was used quasy experimental design and the population was breast cancer patient undergoing chemotherapy in RSUD Ibnu Sina Gresik in June 2012. The 10 respondents who met inclusion criteria were taken with matching allocation technique and divided into control and case group. CRF were collected by a subjective instrument called Brief Fatigue Inventory (BFI), then analyzed using Wilcoxon signed rank test and Mann Whitney test with signification value was α≤0,05.Result: Result of Wilcoxon signed rank test showed that CRF scale in pre-test was different compared to CRF in post-test of case group (p=0.043). Mann Whitney test showed the comparison of post-test scores in both of groups was different (p=0.009). It can be concluded that WEP has effect to CRF.Discussion: The result showed that WEP could decrease CRF in breast cancer patient undergoing chemotheraphy in RSUD. Ibnu Sina Gresik. It is recommended to apply WEP as one of fatigue management in breast cancer patient undergoing chemotherapy. Further study should use WEP and psychosocial therapy to manage CRF in each fatigue dimension to reduce more scale of fatigue in patient.

scholarly journals PENGARUH KOMBINASI TERAPI WALKING EXERCISE DAN TERAPI MUSIK KLASIK TERHADAP FATIGUE PADA PASIEN KANKER PAYUDARA

2020 ◽  
Vol 6 (1) ◽  
pp. 51-56
Author(s):  
Anna Rufaida ◽  
Esti Yunitasari ◽  
Ilya Krisnana
Keyword(s):  
Breast Cancer ◽  
Music Therapy ◽  
Cancer Patients ◽  
Classical Music ◽  
Rank Test ◽  
Breast Cancer Patients ◽  
Signed Rank ◽  
Before And After ◽  
Signed Rank Test ◽  
Walking Exercise

Background: Fatigue is a subjective feeling of physical, cognitive, emotional fatigue related to cancer or cancer treatment and fatigue that is felt to be not comparable to the activities carried out. Side effects that occur can interfere with before weighting, during or after treatment. Walking exercise, has been recognized as one of the most effective interventions to reduce cancer-related fatigue, so this non-pharmacological treatment can be an alternative option that can be done. Music therapy can also have a positive effect on patients with breast cancer. The purpose of this study was to analyze the effect of a combination of walking exercise and classical music therapy on fatigue in breast cancer patients. Method: this study is a quasi experimental study. The study sample was breast cancer patients who visited Surabaya health centers who met the criteria of inclusion and exclusion by simple random sampling (n = 48). The independent variable in this study was a combination of walking exercise and listening to classical music. The dependent variable is fatigue. Giving intervention combination of walking exercise and listening to classical music through module media and mp3. Measurement of fatigue using BFI (Brief Fatigue Inventory). The intervention was given for 3 weeks and carried out 3 measurements (pre test and post test). Test of statistical analysis using Wilcoxone signed rank test Results: In the treatment group there were differences in the value of fatigue before and after 4 weeks of interventions with combination walking and classical music. There were differences in fatigue before and after 4 weeks of walking exercise and classical music with sig values ​​<0.05. In the control group the results of the Wilcoxone signed rank test showed no significant differences in fatigue before and after the 4th week of evaluation with a value of 0.04. Conclusion: Combination of walking exercise and listening to classical music can reduce fatigue in breast cancer patients.   Keywords: walking exercise, music, fatigue, exercise, classical music, Mozart

scholarly journals Presentation Intervals And The Impact Of Delay On Breast Cancer Progression In A Black African Population

2020 ◽  
Author(s):  
Olayide Agodirin ◽  
Samuel Olatoke ◽  
Ganiyu Rahman ◽  
Julius Olaogun ◽  
Olalekan Olasehinde ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Healthcare Provider ◽  
Help Seeking ◽  
Locally Advanced ◽  
Rank Test ◽  
Signed Rank ◽  
Wilcoxon Signed Rank Test ◽  
Signed Rank Test ◽  
The Impact

Abstract BACKGROUND: The help-seeking interval or the primary-care interval are points of delays in breast cancer presentation. To inform future breast cancer down-staging intervention, we described the contribution of each interval to the delay and the impact of delay on tumor progression.METHOD: Multicentered survey from June 2017 to May 2018. We hypothesized that most patients visited the First Healthcare Provider within 60days of tumor detection. Inferential statistics were by t-test, chi-square test, and Wilcoxon-Signed Rank test at p-value 0.05 or 95% confidence limits. Time-to-event was by survival method. Multivariate analysis was by logistic regression.RESULTS: Respondents were females between 24 and 95 years (n=420). Most respondents visited FHP within 60 days of detecting symptoms (230(60%, 95% CI 53-63). Most had long primary-care(237 of 377(64% 95%CI 59-68) and detection-to-specialist(293 (73% (95%CI 68-77)) intervals. The primary care interval(median 106days) was longer than the help-seeking interval( median 42days )Wilcoxon signed-rank test p= 0.001. There was strong correlation between length of primary care interval and the detection-to-specialist interval(r= 0.9, 95%CI 0.88- 0.92). Patronizing the hospital, receiving the correct advice, and having a big tumor(>5cm) were associated with short intervals. Tumors were detected early, but most became advanced before arriving at the specialist clinic. The difference in tumor size between detection and arriving at a specialist clinic was 5.0±4.9cm(95%CI 4.0-5.0). The instantaneous hazard of progressing from early to locally advanced disease was least in the first 30days(3%). The hazard was 31% in 90days.CONCLUSION: Most respondents presented early to the first healthcare provider, but most arrived late at a specialist clinic. The primary care interval was longer than the help-seeking interval. Most tumors were early at detection but locally advanced before arriving in a specialist clinic. Interventions aiming to shorten the primary care interval will have the most impact on time to breast cancer presentation for specialist oncology care in Nigeria.

scholarly journals Presentation Intervals and the Impact of Delay on Breast Cancer Progression in a Black African Population.

2020 ◽  
Author(s):  
Olayide Agodirin ◽  
Samuel Olatoke ◽  
Ganiyu Rahman ◽  
Julius Olaogun ◽  
Olalekan Olasehinde ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Healthcare Provider ◽  
Help Seeking ◽  
Locally Advanced ◽  
Rank Test ◽  
Signed Rank ◽  
Wilcoxon Signed Rank Test ◽  
Signed Rank Test ◽  
The Impact

Abstract BACKGROUND: The help-seeking interval or the primary-care interval are points of delays in breast cancer presentation. To inform future breast cancer down-staging intervention, we described the contribution of each interval to the delay and the impact of delay on tumor progression.METHOD: Multicentered survey from June 2017 to May 2018. We hypothesized that most patients visited the First Healthcare Provider within 60days of tumor detection. Inferential statistics were by t-test, chi-square test, and Wilcoxon-Signed Rank test at p-value 0.05 or 95% confidence limits. Time-to-event was by survival method. Multivariate analysis was by logistic regression.RESULTS: Respondents were females between 24 and 95 years (n=420). Most respondents visited FHP within 60 days of detecting symptoms (230 (60%, 95% CI 53-63). Most had long primary-care (237 of 377 (64% 95%CI 59-68) and detection-to-specialist (293 (73% (95% CI 68-77)) intervals. The primary care interval (median 106days) was longer than the help-seeking interval ( median 42days ) Wilcoxon signed-rank test p= 0.001. There was strong correlation between length of primary care interval and the detection-to-specialist interval (r= 0.9, 95% CI 0.88- 0.92). Patronizing the hospital, receiving the correct advice, and having a big tumor (>5cm) were associated with short intervals. Tumors were detected early, but most became advanced before arriving at the specialist clinic. The difference in tumor size between detection and arriving at a specialist clinic was 5.0±4.9cm (95% CI 4.0-5.0). The instantaneous hazard of progressing from early to locally advanced disease was least in the first 30 days(3%). The hazard was 31% in 90 days.CONCLUSION: Most respondents presented early to the first healthcare provider, but most arrived late at a specialist clinic. The primary care interval was longer than the help-seeking interval. Most tumors were early at detection but locally advanced before arriving in a specialist clinic. Interventions aiming to shorten the primary care interval will have the most impact on time to breast cancer presentation for specialist oncology care in Nigeria.

Sign in / Sign up

Export Citation Format

Share Document